Lilly acquires Centessa Pharmaceuticals to enhance sleep-wake disorder treatments
Eli Lilly has completed its acquisition of Centessa Pharmaceuticals, focusing on orexin receptor 2 agonists.
| Drug | MOA / Company | Stage |
|---|---|---|
| Lead Asset | Eli Lilly | Lead |
Focal Asset
Lead Asset
Company
Eli Lilly
Indication
Neurology / Sleep-Wake Disorders
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
Lilly's acquisition of Centessa Pharmaceuticals significantly enhances its capabilities in the sleep-wake disorder therapeutic area, particularly with innovative orexin receptor 2 agonists. This strategic move positions Lilly to potentially lead in a competitive market, impacting both its pipeline and market dynamics.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the progress of Centessa's orexin receptor 2 agonists and any upcoming clinical trial results.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.